Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARCT Arcturus Therapeutics	$12.63 -0.8%	$11.30	$8.04 ▼ $45.00	$342.54M	2.36	448,889 shs	1.00 million shs
IGMS IGM Biosciences	$1.28 -3.8%	$1.22	$0.92 ▼ $22.50	$76.51M	0.61	313,450 shs	365,535 shs
TRDA Entrada Therapeutics	$7.66 -3.0%	$8.35	$7.10 ▼ $21.79	$290.72M	0.04	132,134 shs	360,715 shs
TSHA Taysha Gene Therapies	$2.71 -1.5%	$1.92	$1.05 ▼ $4.32	$581.73M	0.9	3.01 million shs	5.62 million shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARCT Arcturus Therapeutics	-0.79%	+3.52%	-1.41%	-24.78%	-65.60%
IGMS IGM Biosciences	-3.76%	+2.40%	-7.58%	-5.88%	-85.92%
TRDA Entrada Therapeutics	-3.04%	+2.13%	-16.10%	-35.85%	-50.23%
TSHA Taysha Gene Therapies	-1.45%	-1.45%	+39.69%	+69.38%	-14.51%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARCT Arcturus Therapeutics	2.8319 of 5 stars	4.6	0.0	0.0	2.5	2.5	0.6
IGMS IGM Biosciences	4.0065 of 5 stars	3.0	1.0	4.6	2.1	3.3	1.3
TRDA Entrada Therapeutics	2.7683 of 5 stars	3.6	2.0	0.0	2.7	1.7	1.3
TSHA Taysha Gene Therapies	3.3706 of 5 stars	4.5	1.0	0.0	3.3	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARCT Arcturus Therapeutics	3.11	Buy	$53.50	323.59% Upside
IGMS IGM Biosciences	1.90	Reduce	$5.50	329.69% Upside
TRDA Entrada Therapeutics	3.25	Buy	$25.67	235.07% Upside
TSHA Taysha Gene Therapies	3.00	Buy	$7.00	158.30% Upside

Current Analyst Ratings Breakdown

Latest IGMS, TRDA, ARCT, and TSHA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/29/2025	TSHA Taysha Gene Therapies	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/29/2025	TSHA Taysha Gene Therapies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$5.00 ➝ $6.00
5/29/2025	TSHA Taysha Gene Therapies	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $9.00
5/28/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$32.00
5/20/2025	TRDA Entrada Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
5/16/2025	TSHA Taysha Gene Therapies	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$8.00 ➝ $9.00
5/14/2025	ARCT Arcturus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$50.00 ➝ $45.00
5/13/2025	ARCT Arcturus Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/13/2025	ARCT Arcturus Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$68.00 ➝ $66.00
4/28/2025	TSHA Taysha Gene Therapies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$5.00 ➝ $5.00
4/28/2025	TSHA Taysha Gene Therapies	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$7.00 ➝ $7.00

(Data available from 5/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARCT Arcturus Therapeutics	$131.27M	2.61	N/A	N/A	$10.42 per share	1.21
IGMS IGM Biosciences	$2.68M	28.54	N/A	N/A	$3.46 per share	0.37
TRDA Entrada Therapeutics	$172.22M	1.69	N/A	N/A	$7.26 per share	1.06
TSHA Taysha Gene Therapies	$7.22M	80.53	N/A	N/A	$0.40 per share	6.78

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARCT Arcturus Therapeutics	-$29.73M	-$2.53	N/A	N/A	N/A	-36.39%	-22.39%	-14.81%	8/4/2025 (Estimated)
IGMS IGM Biosciences	-$246.42M	-$3.27	N/A	N/A	N/A	-7,534.03%	-155.42%	-61.04%	8/13/2025 (Estimated)
TRDA Entrada Therapeutics	-$6.68M	$0.81	4.82	N/A	N/A	25.53%	16.11%	10.39%	8/12/2025 (Estimated)
TSHA Taysha Gene Therapies	-$111.57M	-$0.34	4.30	N/A	N/A	-229.67%	-106.36%	-49.16%	8/11/2025 (Estimated)

Latest IGMS, TRDA, ARCT, and TSHA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	TSHA Taysha Gene Therapies	-$0.08	-$0.08	N/A	-$0.08	$1.48 million	$2.30 million
5/13/2025	Q1 2025	IGMS IGM Biosciences	-$0.41	-$0.86	-$0.45	-$0.86	$4.25 million	$0.50 million
5/12/2025	Q1 2025	ARCT Arcturus Therapeutics	-$1.58	-$0.52	+$1.06	-$0.52	$25.64 million	$29.38 million
5/8/2025	Q1 2025	TRDA Entrada Therapeutics	-$0.78	-$0.42	+$0.36	-$0.42	$10.98 million	$8.75 million
3/6/2025	Q4 2024	ARCT Arcturus Therapeutics	-$0.33	-$1.11	-$0.78	-$1.11	$44.64 million	$22.77 million
3/6/2025	Q4 2024	IGMS IGM Biosciences	-$0.74	-$0.61	+$0.13	-$0.61	$0.39 million	$0.41 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARCT Arcturus Therapeutics	$0.71	5.66%	N/A	N/A	N/A
IGMS IGM Biosciences	N/A	N/A	N/A	N/A	N/A
TRDA Entrada Therapeutics	N/A	N/A	N/A	N/A	N/A
TSHA Taysha Gene Therapies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARCT Arcturus Therapeutics	N/A	4.76	4.76
IGMS IGM Biosciences	N/A	5.22	5.22
TRDA Entrada Therapeutics	N/A	6.59	6.59
TSHA Taysha Gene Therapies	0.48	5.51	5.51

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARCT Arcturus Therapeutics	94.54%
IGMS IGM Biosciences	42.79%
TRDA Entrada Therapeutics	86.39%
TSHA Taysha Gene Therapies	77.70%

Insider Ownership

Company	Insider Ownership
ARCT Arcturus Therapeutics	16.60%
IGMS IGM Biosciences	57.00%
TRDA Entrada Therapeutics	8.11%
TSHA Taysha Gene Therapies	2.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARCT Arcturus Therapeutics	180	27.12 million	22.94 million	Optionable
IGMS IGM Biosciences	190	59.78 million	25.57 million	Optionable
TRDA Entrada Therapeutics	110	37.95 million	34.58 million	Optionable
TSHA Taysha Gene Therapies	180	214.66 million	199.41 million	Optionable

IGMS, TRDA, ARCT, and TSHA Headlines

Recent News About These Companies

Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Expected to Rise, JMP Securities Analyst Says

May 31 at 1:52 AM | americanbankingnews.com

Taysha Gene Therapies Announces Pivotal Part B Trial Design Details for TSHA-102 in Rett Syndrome Enabled by IRSF Natural History Data and Positive Clinical Data from Part A of ...

May 30 at 2:59 PM | morningstar.com

Taysha Gene Therapies (TSHA) Price Target Raised by JMP on Positive Rett Syndrome Trial Data

May 30 at 2:59 PM | msn.com

Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up on Analyst Upgrade

May 30 at 10:05 AM | marketbeat.com

JMP Securities Issues Positive Forecast for Taysha Gene Therapies (NASDAQ:TSHA) Stock Price

May 30 at 10:02 AM | marketbeat.com

Chardan Capital Issues Positive Forecast for Taysha Gene Therapies (NASDAQ:TSHA) Stock Price

May 30 at 8:16 AM | marketbeat.com

Taysha Gene Therapies (NASDAQ:TSHA) Price Target Raised to $9.00

May 30 at 3:19 AM | americanbankingnews.com

Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up Following Analyst Upgrade

May 30 at 1:49 AM | americanbankingnews.com

Taysha: TSHA-102 Presses On With IND Part B Protocol And SAP Amendments

May 29 at 5:07 PM | seekingalpha.com

Taysha stock surges on positive trial design and FDA alignment

May 29 at 4:28 PM | investing.com

Taysha, FDA Align on Plan for Pivotal Rett Syndrome Gene Therapy Trial

May 29 at 4:28 PM | precisionmedicineonline.com

Stocks to Watch: Nvidia, HP, Taysha Gene Therapies

May 29 at 11:27 AM | marketwatch.com

Taysha Shares Jump 19% Following Favorable Trial Design and FDA Feedback for Rett Syndrome Therapy

May 29 at 11:27 AM | msn.com

Taysha Gene Therapies, Inc. (TSHA)’s TSHA-102 Shows Promising Results in Rett Syndrome Patients Aged 6+

May 29 at 12:57 AM | insidermonkey.com

Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

May 28 at 10:40 PM | globenewswire.com

Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

May 28 at 4:02 PM | globenewswire.com

Taysha Gene Therapies Announces Pivotal Part B Trial Design Details for TSHA-102 in Rett Syndrome Enabled by IRSF Natural History Data and Positive Clinical Data from Part A of the REVEAL Adult/Adolescent and Pediatric Trials Evaluating TSHA-102

May 28 at 4:01 PM | globenewswire.com

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $6.57 Consensus PT from Brokerages

May 28 at 2:39 AM | americanbankingnews.com

Reviewing Taysha Gene Therapies (NASDAQ:TSHA) & Quince Therapeutics (NASDAQ:QNCX)

May 28 at 1:51 AM | americanbankingnews.com

Taysha Gene Therapies’ SWOT analysis: promising gene therapy stock faces pivotal year

May 27, 2025 | investing.com

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Recommendation of "Buy" from Brokerages

May 26, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IGMS, TRDA, ARCT, and TSHA Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

$12.63 -0.10 (-0.79%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$12.60 -0.03 (-0.25%)

As of 05/30/2025 05:54 PM Eastern

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

IGM Biosciences NASDAQ:IGMS

$1.28 -0.05 (-3.76%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$1.27 -0.01 (-0.78%)

As of 05/30/2025 07:59 PM Eastern

IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

Entrada Therapeutics NASDAQ:TRDA

$7.66 -0.24 (-3.04%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$7.60 -0.06 (-0.78%)

As of 05/30/2025 04:20 PM Eastern

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Taysha Gene Therapies NASDAQ:TSHA

$2.71 -0.04 (-1.45%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$2.68 -0.04 (-1.29%)

As of 05/30/2025 07:55 PM Eastern

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time